pte20181115001 Medicine / Vellness, Research / Technology
Parkinson: Blockade of proteins destroys clots
Studied human brains – Tests with the USP13 molecule were successfully performed in mice
Blinking hands: they hope a new treatment approach (Photo: pikelio.de, R. B.)
Researchers at the George Washington University Medical Center (GUMC), http: //gumc.georgetov.edu can not only dissolve specific clots of Parkinson's alpha-synuclein protein in the brain, but also degrade. Studies with mice and human brains show: One of the reasons for these so-called. The left body is that the USP13 molecule removed all the markers into alpha-synuclein that characterize this protein for destruction.
Ubikuitin as the key
The results published in "Human Molecular Genetics" show that blocking USP13 in Parkinson's mice models not only removes Levi's bodies, but also prevents reconstruction. The label, which removes USP13, is called ubiquitin. It denotes the protein alpha-sinukulin for degradation.
According to the head of the Xiaoguang Liu research, the current study provides new evidence that USP13 can be a therapeutic target for Parkinson's and other disorders. There are three types of motor disorders associated with alpha-synuclein accumulation: Parkinson's, left ventricular dementia, and multiple systemic atrophy.
At the beginning of the study, the team investigated the human brain. They included eleven brains from Parkinson's disease patients and a control group of nine healthy individuals. Autopsies were performed between four and twelve hours after death. It was found that levels of USP13 in the middle wall of Parkinson's patients were significantly increased.
In the next step, Parkinson mice models showed that the deactivation of the USP13 gene can improve the ubiquity of alpha-synuclein and thus its degradation. In addition, deactivation of USP13 protected mice against neuronal death induced by alpha-synuclein, as explored by senior author Charbel Moussa. Animals have improved motor skills. The level of Parkin protein has been increased and alpha-synucleulin has been degraded. In addition, the effect of protein kinase inhibitors nilotinib has also been improved. This drug is approved in the United States for the treatment of certain forms of cancer.